Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine

Journal of Pediatric Hematology/oncology
Iren ShabanovaRobert J Klaassen

Abstract

The distinction between myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) often relies on an arbitrary marrow blast cutoff of 30% in pediatrics and 20% in adults. There is little data about the treatment of children with extramedullary myeloid malignancy that has features of both, MDS and AML. Herein, we report for the first time 2 patients MDS/AML (1 with Shwachman-Diamond syndrome and 1 with idiopathic MDS and monosomy 7) who presented with extramedullary complications, received treatment with azacitidine, achieved complete remission and subsequently underwent hematopoietic stem cell transplantation.

References

Jan 1, 1977·Scandinavian Journal of Haematology·P C HuijgensO G Muntinghe
Jul 1, 1978·British Medical Journal·M J StrevensR B Williams
Sep 1, 1981·The Journal of Pediatrics·W G WoodsW Krivit
Aug 1, 1996·British Journal of Haematology·O P SmithP Milla
Nov 14, 1997·British Journal of Haematology·I DokalJ Goldman
Aug 16, 2002·British Journal of Haematology·Yigal Dror, Melvin H Freedman
Oct 9, 2002·Journal of Pediatric Hematology/oncology·Karen MandelMelvin H Freedman
Dec 24, 2002·Nature Genetics·Graeme R B BoocockJohanna M Rommens
Dec 24, 2011·Annals of the New York Academy of Sciences·Yigal DrorJohnson M Liu
Jun 4, 2014·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Jul 12, 2017·Critical Reviews in Oncology/hematology·Andre C SchuhHervé Dombret

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
biopsy
flow cytometry

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.